Silence Therapeutics PLC - Post year end business update
(World News Science)

Post year end business update 8 January 2018 Silence Therapeutics plc, AIM:SLN (`Silence` or `the Company`) a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a post year end update. Arrowhead disposal and net cash position In December 2016, given the dramatic decline in the valuation of Arrowhead Pharmaceuticals post clinical halts after discussion with the FDA, the Board decided to deploy our balance sheet to take a c10% stake in Arrowhead with a view to and desire for a strategic transaction. Despite multiple attempts at direct dialogue with Arrowhead, and in particular due to the poison...